Ancora Advisors’s Regenxbio RGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12K Hold
1,000
﹤0.01% 1436
2026
Q1
$8.38K Hold
1,000
﹤0.01% 1821
2025
Q4
$14.4K Hold
1,000
﹤0.01% 1677
2025
Q3
$9.65K Hold
1,000
﹤0.01% 1395
2025
Q2
$8.21K Hold
1,000
﹤0.01% 1407
2025
Q1
$7.15K Hold
1,000
﹤0.01% 1374
2024
Q4
$7.73K Hold
1,000
﹤0.01% 1379
2024
Q3
$10.5K Hold
1,000
﹤0.01% 1317
2024
Q2
$11.7K Hold
1,000
﹤0.01% 1271
2024
Q1
$21.1K Hold
1,000
﹤0.01% 1185
2023
Q4
$17.9K Hold
1,000
﹤0.01% 1184
2023
Q3
$16.5K Hold
1,000
﹤0.01% 1185
2023
Q2
$20K Hold
1,000
﹤0.01% 1136
2023
Q1
$18.9K Hold
1,000
﹤0.01% 1147
2022
Q4
$23K Hold
1,000
﹤0.01% 1147
2022
Q3
$26K Hold
1,000
﹤0.01% 1276
2022
Q2
$25K Hold
1,000
﹤0.01% 1381
2022
Q1
$33K Hold
1,000
﹤0.01% 1409
2021
Q4
$33K Hold
1,000
﹤0.01% 1420
2021
Q3
$42K Hold
1,000
﹤0.01% 1252
2021
Q2
$39K Hold
1,000
﹤0.01% 1176
2021
Q1
$34K Hold
1,000
﹤0.01% 1180
2020
Q4
$45K Hold
1,000
﹤0.01% 899
2020
Q3
$28K Hold
1,000
﹤0.01% 960
2020
Q2
$37K Hold
1,000
﹤0.01% 882
2020
Q1
$32K Hold
1,000
﹤0.01% 975
2019
Q4
$41K Buy
+1,000
New +$39.5K ﹤0.01% 933

Other funds holding RGNX

Ancora Advisors's RGNX Position: Q2 2026 in Review

Ancora Advisors held its Regenxbio (RGNX) position steady in Q2 2026 at 1,000 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1436.

Ancora Advisors first reported a position in RGNX in Q4 2019 and has held it in 27 quarters since. The position peaked at $45K in Q4 2020. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Ancora Advisors held 1,000 shares of Regenxbio worth $12K as of Q2 2026.
  • Ancora Advisors left its Regenxbio share count unchanged in Q2 2026.
  • Regenxbio made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1436 holding.
  • Ancora Advisors first reported a position in Regenxbio in Q4 2019 and has held it in 27 quarters since.
  • Ancora Advisors's Regenxbio position peaked at $45K in Q4 2020.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.